Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides

Invest New Drugs. 2023 Feb;41(1):153-161. doi: 10.1007/s10637-023-01333-y. Epub 2023 Feb 7.

Abstract

One of the features that differentiate cancer cells is their increased proliferation rate, which creates an opportunity for general anti-tumor therapy directed against the elevated activity of replicative apparatus in tumor cells. Besides DNA synthesis, successful genome replication requires the reparation of the newly synthesized DNA. Malfunctions in reparation can cause fatal injuries in the genome and cell death. Recently we have found that the ultra-short single-stranded deoxyribose polynucleotides of random sequence (ssDNA) effectively inhibit the catalytic activity of DNA polymerase [Formula: see text]. This effect allowed considering these substances as potential anti-tumor drugs, which was confirmed experimentally both in vitro (using cancer cell cultures) and in vivo (using cancer models in mice). According to the obtained results, ssDNA significantly suppresses cancer development and tumor growth, allowing consideration of them as novel candidates for anti-cancer drugs.

Keywords: Cancer; DNA repair; Single-stranded DNA; cytostatics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • DNA Replication
  • DNA*
  • DNA, Single-Stranded
  • DNA-Binding Proteins / genetics
  • Mice
  • Polydeoxyribonucleotides*

Substances

  • Polydeoxyribonucleotides
  • DNA
  • DNA, Single-Stranded
  • DNA-Binding Proteins